Taysha gene therapies announces presentation on new preclinical data for tsha-102 in rett syndrome at upcoming american society of gene and cell therapy 26th annual meeting

Dallas, april 27, 2023 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a clinical-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns), today announced that an abstract related to its tsha-102 program in rett syndrome was accepted for presentation at the upcoming american society of gene and cell therapy (asgct) 26th annual meeting, taking place in los angeles, ca from may 16-20, 2023. the abstract includes new preclinical data from a taysha-sponsored study for tsha-102, a self-complementary intrathecally delivered aav9 gene transfer therapy in clinical evaluation for rett syndrome, a rare neurodevelopmental disorder caused by mutations in the x-linked mecp2 gene.
TSHA Ratings Summary
TSHA Quant Ranking